JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy

Filters
Title Author Hits
Bridging Data and Healthcare in the Nordics Written by: J. Smith Hits: 58
How Well Do My CGM and BGM Readings Match? Written by: J. Smith Hits: 132
Epigenetic Clues to Heart Risk in Type 2 Diabetes Written by: J. Smith Hits: 89
Could a Gut Bacterium Help Transform Diabetes and Obesity Care? Written by: J. Smith Hits: 159
Why mRNAs Are a Good Option for Vaccines Written by: J. Smith Hits: 332
Why I Took Medical Courses to Strengthen My Data Skills Written by: J. Smith Hits: 127
New Research Reveals the Hidden Complexity of Insulin Resistance Written by: J. Smith Hits: 266
What the 2025 Diabetes Care Updates Mean for You Written by: J. Smith Hits: 259
How an Hour-by-Hour View Transforms Time in Range Insights Written by: J. Smith Hits: 183
Successfully Completed: Diabetes – A Global Challenge Written by: J. Smith Hits: 235
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9

Page 1 of 9

Articles

  • The Economic Impact of Weight-Loss Drugs: A Trillion-Dollar Boost?
  • Novo Nordisk Announces Positive Results in Phase 3a Trial of IcoSema, a Combination of Semaglutide and Insulin Icodec for Type 2 Diabetes
  • Understanding Obesity: Beyond the Scale
  • FDA's Ongoing Evaluation of GLP-1 RAs: No Clear Link Found Between Medication and Suicidal Thoughts or Actions
  • Managing Type 2 Diabetes: The Power of Combining GLP-1 Medicines with FreeStyle Libre Technology
  • Navigating Prior Authorization for Type 2 Diabetes Treatments
  • Exploring the Neuroprotective Potential of GLP-1: A New Frontier in Medical Research
  • The Mounjaro Supply Challenges: Looking Back and Looking Forward
  • New Research Reveals the Hidden Complexity of Insulin Resistance
  • Tips for Using a OneTouch Verio Flex Meter
  • Walking Your Way to Better Blood Sugar Control
  • Novo Nordisk's Stance on Semaglutide for Cosmetic Use
  • Addressing Misconceptions: A Closer Look at Weight Loss Drugs and Their Role in Managing Obesity and Type 2 Diabetes
  • Semaglutide's Breakthrough in Kidney Disease Management
  • The Manufacturing Costs and Supply Chain Dynamics of Diabetes Drugs
  • What the 2025 Diabetes Care Updates Mean for You
  • Diabetes and Heart Health: A Crucial Connection
  • Subtle Yet Significant Changes: The 2024 ADA Standards of Care in Diabetes
  • Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
  • Managing Blood Sugar with GLP-1 Medications: Foods to Avoid and Healthier Alternatives

News

October 2025

  • FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
  • Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
  • Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
  • Semaglutide’s Heart Benefits Extend Beyond Weight Loss
  • Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

  • CVS Caremark Faces Lawsuit Over Dropping Zepbound
  • Dexcom Introduces Smart Basal at EASD 2025
  • Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
  • Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
  • Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
  • Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
  • Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

  • FDA Approves Wegovy for MASH Treatment
  • FDA Expands Repatha Access to More High-Risk Adults
  • Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
  • Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
  • Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
  • Signos Press Release Raises Questions About FDA Clearance Claims
  • Teva Launches First Generic GLP-1 for Obesity
  • Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

  • Type 2 Diabetes
  • Novo Nordisk
  • Semaglutide
  • Obesity Treatment
  • GLP-1
  • Wegovy
  • Eli Lilly
  • Tirzepatide
  • Ozempic
  • Zepbound
  • Diabetes
  • Obesity
  • FDA Approval
  • Diabetes Management
  • Cardiovascular Health
  • Mounjaro
  • SELECT Trial
  • Continuous Glucose Monitoring
  • GLP-1 Therapy
  • Obesity Management
  • Metabolic Health
  • Orforglipron
  • Disease Modification
  • Dexcom
  • CGM
  • Rybelsus
  • Clinical Trials
  • Oral Semaglutide
  • FDA
  • Diabetes Treatment

Contact Us

Search

5K@ADA

5K@EASD

World Obesity Day

Rochen Web Hosting

Bluesky Social

  • You are here:  
  • Home
  • Articles
 
Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.